Premium
Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
Author(s) -
Ottmann Oliver G.,
MüllerTidow Carsten,
Krämer Alwin,
Schlenk Richard F.,
Lübbert Michael,
Bug Gesine,
Krug Utz,
Bochtler Tilmann,
Voss Florian,
Taube Tillmann,
Liu Dan,
GarinChesa Pilar,
Döhner Hartmut
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15204
Subject(s) - cytarabine , medicine , refractory (planetary science) , plk1 , oncology , phases of clinical research , myeloid , myeloid leukemia , clinical trial , cancer , cell cycle , biology , astrobiology